Fritextsökning
Innehållstyper
-
Multiple rotor options in refrigerated microcentrifuge
The new 5430 R from Eppendorf is a refrigerated microcentrifuge with several different rotors.
-
Ny teknik kan upptäcka alzheimer tidigare
Detektion av specifika former av proteinet tau i blodprover kan ge tidigare diagnostik av personer med alzheimer, redan innan de första symptomen uppstår.
-
Swedish top scientists to EMBO
Two Swedish top scientists will have a really good chance to influence European life science research from now on. One is from the Karolinska Institutet, and on...
-
New member to Active board
The Election Committee of Active Biotech proposes a very experienced financial sector executive to join the company board. Five existing members are also to be ...
-
Top modern lab to Sahlgrenska
The Sahlgrenska Science Park will soon open the doors to a brand new wet laboratory.
-
New nanotech professor to DTU
The Danish University of Technology, DTU, has appointed Kristoffer Almdal as professor to DTU Nanotech.
-
Travelling scholarship to DTU professor
The Vera og Carl Johan Michaelsens Rejselegat has the founder of the Medicine and Technology program at DTU with a scholarship.
-
Vitrolife wants to acquire Medicult
The Swedish company Vitrolife intends to make en exchange offer to the shareholders of the Danish company Medicult to acquire all outstanding shares in the company.
-
Google och Abbvie i miljardsamarbete
Googles spinoff-bolag Calico ingår ett samarbete med läkemedelsjätten Abbvie.
-
"Konsulter ger oss nya perspektiv"
Pernilla Sandwall, Chief Operating Officer på Index Pharmaceutcals, berättade på Life Science Swedens event Pharma Outsourcing om bolagets modell för outsourcing.
-
New influenza vaccine to EU
The Astrazeneca subsidary Medimmune submits marketing authorisationapplication in EU for an new intranasal vaccine against influenza.
-
New tools to fight bacteria
Better guidelines for doctors, detailed patient journals, and national monitoring systems are some of the tools needed to combat the increasing problem of antib...
-
Meda gets access to Asia
The biotech giant Meda has recently acquires world-wide rights to the cancer breakthrough pain drug Onsolis.
-
Time to save for survival
The future is bright for the biotech industry. However, the companies need to cut costs immediately if they want to survive the rough economic times.
-
Orexo opens doors eastwards
The drug delivery company has signed a deal for selling a cancer pain treatment in China. "An ideal partner for us" says Torbjörn Bjerke, CEO of Orexo.
-
Young, bright and committed to labtech
Ghazal Voghoui recently bought her first apartment and finally settled in Stockholm again. Last year, she finished her law studies and she is relieved to be bac...
-
Diagnostics to deal with new diseases
Maria Brytting at the Swedish Institute for Infectious Disease Control, SMI, will share her experiences from April 2009 when the new influenza A virus, H1N1, wa...
-
View pathology images in your iPhone
The Institute for Medical Informatics in Oslo announces a brand new iPhone application for virtual microscopy.
-
Näthandeln är en stor utmaning för småföretagarna
Att sätta upp en webbshop är enkelt idag. Men att ranka högt på Google är betydligt svårare.
-
Tom Britton: ”Nivån för flockimmunitet är lägre än vad vi trott”
Nya matematiska modeller pekar på att flockimmunitetsnivån är kraftigt lägre än vad man tidigare trott, och att immuniteten i dagsläget spelar en större roll, e...
-
With their hands on the legal levers
It is wonderful news for the Scandinavian scientific community. At the end of May it stood clear that Lund will host to the European Spallation Source.
-
Unga forskare prisas
Upptäckt koppling mellan tarmfloran och fetma belönas när pris för unga forskare delas ut i Stockholm.
-
Väntar sig patent
Follicum får preliminärt godkännande från Europapatentverket.
-
Success fee to Bioinvent and partner
The cancer collaboration started last year. After successful technology transfer the two partner companies now receives 5 million euro from pharma giant Roche.